Table of Contents

Phencyclidine (PCP, Ketamine) Use Disorder

Primer

Phencyclidine (PCP) Use Disorder is a substance use disorder characterized by a problematic pattern of PCP (or PCP-like substances such as ketamine) leading to clinically significant impairment or distress.

Epidemiology
Prognosis
Risk Factors

DSM-5 Diagnostic Criteria

Criterion A

A pattern of phencyclidine (or a pharmacologically similar substance like ketamine) use leading to clinically significant impairment or distress, as manifested by at least 2 of the following, occurring within a 12-month period:

  1. Phencyclidine is often taken in larger amounts or over a longer period than was intended.
  2. There is a persistent desire or unsuccessful efforts to cut down or control phencyclidine use.
  3. A great deal of time is spent in activities necessary to obtain phencyclidine, use the phencyclidine, or recover from its effects.
  4. Craving, or a strong desire or urge to use phencyclidine.
  5. Recurrent phencyclidine use resulting in a failure to fulfill major role obligations at work, school, or home (e.g. - repeated absences from work or poor work performance related to phencyclidine use; phencyclidine-related absences, suspensions, or expulsions from school; neglect of children or household).
  6. Continued phencyclidine use despite having persistent or recurrent social or inter personal problems caused or exacerbated by the effects of the phencyclidine (e.g. - arguments with a spouse about consequences of intoxication; physical fights).
  7. Important social, occupational, or recreational activities are given up or reduced because of phencyclidine use.
  8. Recurrent phencyclidine use in situations in which it is physically hazardous (e.g. - driving an automobile or operating a machine when impaired by a phencyclidine).
  9. Phencyclidine use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the phencyclidine.
  10. Tolerance, as defined by either of the following:
    • A. A need for markedly increased amounts of the phencyclidine to achieve intoxication or desired effect.
    • B. A markedly diminished effect with continued use of the same amount of the phencyclidine.
Note: Withdrawal symptoms and signs are not established for phencyclidines, and so this criterion does not apply. (Withdrawal from phencyclidines has been reported in animals but not documented in human users.)

Specifiers

Remission Specifier

Specify if:

  • In early remission: After full criteria for phencyclidine use disorder were previously met, none of the criteria for phencyclidine use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the phencyclidine,” may be met).
  • In sustained remission: After full criteria for phencyclidine use disorder were previously met, none of the criteria for phencyclidine use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the phencyclidine,” may be met).

Environment Specifier

Specify if:

  • In a controlled environment: This additional specifier is used if the individual is in an environment where access to phencyclidines is restricted.

Severity Specifier

Specify if:

  • Mild: Presence of 2 to 3 symptoms
  • Moderate: Presence of 4 to 5 symptoms
  • Severe: Presence of 6+ symptoms

Signs and Symptoms

PCP and PCP-Like Substances

PCP

Ketamine

Screening and Rating Scales

Pathophysiology

Differential Diagnosis

Investigations

Physical Exam

Treatment

Resources

1) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
2) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
3) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
4) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
5) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
6) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
7) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
8) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
9) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.
11) American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.